Journal Article

DKFZ-2024-01571

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Immune signature of patients with cardiovascular disease predicts increased risk for a severe course of COVID-19.

Günter, M. (First author)DKFZ* ; Mueller, K. A. L. ; Salazar, M. J.DKFZ* ; Gekeler, S. ; Prang, C. ; Harm, T. ; Gawaz, M. P. ; Autenrieth, S. (Last author)DKFZ*

2024
Wiley-VCH Weinheim

This record in other databases:  

Please use a persistent id in citations: doi:10.1002/eji.202451145

Abstract: Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection can lead to life-threatening clinical manifestations. Patients with cardiovascular disease (CVD) are at higher risk for severe courses of COVID-19. So far, however, there are hardly any strategies for predicting the course of SARS-CoV-2 infection in CVD patients at hospital admission. Thus, we investigated whether this prediction is achievable by prospectively analysing the blood immunophenotype of 94 nonvaccinated participants, including uninfected and acutely SARS-CoV-2-infected CVD patients and healthy donors, using a 36-colour spectral flow cytometry panel. Unsupervised data analysis revealed little differences between healthy donors and CVD patients, whereas the distribution of the cell populations changed dramatically in SARS-CoV-2-infected CVD patients. The latter had more mature NK cells, activated monocyte subsets, central memory CD4+ T cells, and plasmablasts but fewer dendritic cells, CD16+ monocytes, innate lymphoid cells, and CD8+ T-cell subsets. Moreover, we identified an immune signature characterised by CD161+ T cells, intermediate effector CD8+ T cells, and natural killer T (NKT) cells that is predictive for CVD patients with a severe course of COVID-19. Thus, intensified immunophenotype analyses can help identify patients at risk of severe COVID-19 at hospital admission, improving clinical outcomes through specific treatment.

Keyword(s): Cardiovascular disease ; Immune signature ; Immuno‐response ; SARS‐CoV‐2 infection ; Spectral flow cytometry

Note: #EA:D431#LA:D431# / 2024 Nov;54(11):e2451145

---

Contributing Institute(s):

1. Dentritische Zellen bei Infektionen und Krebs (D431)

Research Program(s):

1. 314 - Immunologie und Krebs (POF4-314) (POF4-314)

Appears in the scientific report 2024

---

Database coverage:
; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Life Sciences ; DEAL Wiley ; Essential Science Indicators ; IF >= 5 ; JCR ; Nationallizenz ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---